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Abstract
Introduction Cardiac surgery with cardiopulmonary bypass
(CPB) is associated with the activation of inflammatory
mediators that possess prothrombotic activity and could cause
postoperative haemostatic disorders. This study was conducted
to investigate the effect of cardiac surgery on prothrombotic
activity in children undergoing cardiac surgery for complex
cardiac defects.
Methods Eighteen children (ages 3 to 163 months) undergoing
univentricular palliation with total cavopulmonary connection
(TCPC) (n = 10) or a biventricular repair (n = 8) for complex
cardiac defects were studied. Prothrombotic activity was
evaluated by measuring plasma levels of prothrombin fragment
1+2 (F1+2), thromboxane B2  (TxB2), and monocyte
chemoattractant protein-1 (MCP-1). Anti-thrombotic activity
was evaluated by measuring levels of tissue factor pathway
inhibitor (TFPI) before, during, and after cardiac surgery.
Results In all patients, cardiac surgery was associated with a
significant but transient increase of F1+2, TxB2, TFPI, and
MCP-1. Maximal values of F1+2, TxB2, and MCP-1 were found
at the end of CPB. In contrast, maximal levels of TFPI were
observed at the beginning of CPB. Concentrations of F1+2 at
the end of CPB correlated negatively with the minimal
oesophageal temperature during CPB. Markers of
prothrombotic activity returned to preoperative values from the
first postoperative day on. Early postoperative TFPI levels were
significantly lower and TxB2 levels significantly higher in patients
with TCPC than in those with biventricular repair.
Thromboembolic events were not observed.
Conclusion Our data suggest that children with complex
cardiac defects undergoing cardiac surgery show profound but
transient imbalance between pro- and anti-thrombotic activity,
which could lead to thromboembolic complications. These
alterations are more important after TCPC than after
biventricular repair but seem to be determined mainly by low
antithrombin III.
Introduction
Cardiac surgery with cardiopulmonary bypass (CPB) is asso-
ciated with inflammatory and haemostatic alterations that may
lead to severe bleeding and/or thromboembolic events [1-3].
Abnormalities of the thrombin pathway play a main role in
coagulation and fibrinolysis disorders observed in patients
undergoing CPB [2,3]. A main marker for thrombin generation
is the cleavage of fragment 1+2 from prothrombin (F1+2) [4].
Thrombin is a major activator of platelets. Its activity is associ-
ated with early mortality after coronary artery bypass grafting
operations [5]. Platelet activation goes along with the activa-
tion of the arachidonic acid pathway in platelets and results in
the release of the potent platelet-aggregating agent thrombox-
ane A2, which is rapidly converted into the inactive product
thromboxane B2 (TxB2) [6].
ACT = activated clotting time; AT III = antithrombin III; BV = biventricular; CPB = cardiopulmonary bypass; EDTA = ethylenediaminetetraacetic acid; 
ELISA = enzyme-linked immunosorbent assay; F1+2 = prothrombin fragment 1+2; MCP-1 = monocyte chemoattractant protein-1; PT = prothrombin 
time; PTT = partial thromboplastin time; TCPC = total cavopulmonary connection; TFPI = tissue factor pathway inhibitor; TxB2 = thromboxane B2.Critical Care    Vol 10 No 6    Heying et al.
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Thrombin leads furthermore to tissue factor pathway inhibitor
(TFPI) production [7]. TFPI circulates in plasma as a complex
bound to lipoproteins. Approximately 10% of circulating TFPI
is bound to platelets and is released upon stimulation with
thrombin. TFPI inhibits factor VIIa/TF complex and factor Xa.
Consumption of TFPI offers insight in extrinsic coagulation dis-
orders such as disseminated intravascular coagulation [7,8].
Thrombin also plays a role in inducing the production of mono-
cyte chemoattractant protein-1 (MCP-1) [9]. A wide variety of
cells are capable of producing MCP-1, including leucocytes
and all cell types of the vascular wall. MCP-1 is a chemotactic
factor for monocytes which also stimulates monocyte degran-
ulation, respiratory burst, and tissue factor expression. Figure
1 shows the main role of thrombin in the haemostatic system.
In children with single-ventricle physiology, total cavopulmo-
nary connection (TCPC) is largely accepted as definitive palli-
ation [10,11]. However, besides long-term complications,
patients after TCPC are at high risk for thromboembolic events
due to the non-pulsatile perfusion of the lungs [12-14]. This
study was designed to investigate the influence of cardiac sur-
gery on the balance between pro- and anti-thrombotic activity
in children with complex cardiac defects and to address the
role of univentricular palliation.
Materials and methods
Patients
This study was approved by the Ethical Medical Committee of
the Aachen University of Technology, and written informed
parental consent was obtained.
Clinical data
Eighteen infants and children (ages 3 to 163 months) with
complex cyanotic cardiac defect who were scheduled for car-
diac surgery were enrolled in this prospective study. Patients
were divided into two groups according to the planned opera-
tion: TCPC (n = 10) and biventricular (BV) repair (n = 8).
Genetic, inflammatory, or metabolic diseases were excluded in
all cases. Epidemiological and clinical patient data, including
preoperative medication, are summarised in Table 1.
Anaesthesia
Conventional general anaesthesia consisted of diazepam, fen-
tanyl sulphate, and pancuronium bromide. After induction of
anaesthesia, nasotracheal intubation was performed, and cen-
tral venous and peripheral arterial catheters were inserted.
Perioperative antibiotic prophylaxis consisted of cefotiam
hydrochloride.
Surgical procedure and CPB
The CPB protocol was uniform for all children and was per-
formed with a roller pump, a hollow-fibre membrane oxygena-
tor, and an arterial filter. Anticoagulation was achieved by
heparin sulphate (3 mg/kg body weight) to reach an activated
clotting time (ACT) of more than 400 seconds. Cooling and
rewarming were performed with a heat exchanger. The priming
solution consisted of a crystalloid solution and mannitol (3 ml/
kg). For vasodilatation during the cooling and rewarming peri-
ods, a continuous infusion of sodium nitroprusside was given.
CPB was instituted with a perfusion index of 2.7 litres/minute
per square metre of body surface area. Dexamethasone was
given in a dosage of 3 mg/m2 of body surface area. The aorta
Figure 1
Role of thrombin in the coagulation system Role of thrombin in the coagulation system. Thrombin has a central role in different interactions of the coagulation system as shown. Cleavage of 
prothrombin fragment 1+2 (F1+2) from prothrombin results in thrombin formation. Thrombin production leads to tissue factor pathway inhibitor 
(TFPI) upregulation, which inhibits tissue factor (TF) activity. Monocyte chemoattractant protein-1 (MCP-1) production is also increased via thrombin 
interaction.Available online http://ccforum.com/content/10/6/R165
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was cross-clamped, and cardioplegia was induced by a single
intra-aortic injection of a 4°C cold Bretschneider solution (30
ml/kg). Cardiocirculatory arrest was instituted if necessary,
and the surgical procedure was continued under low-flow per-
fusion (25% of the calculated initial perfusion rate). Rewarm-
ing was achieved under full-flow conditions. The lungs of the
patients were reventilated when core temperature reached
30°C. Neutralisation of heparin was achieved with protamine
sulphate in a 1:1 ratio. During bypass, 14 children received
red blood cell transfusion and 16 children fresh frozen plasma.
Postoperative care
Postoperative monitoring included continuous registration of
heart rate and rhythm, arterial blood pressure, central venous
pressure, and diuresis. Inotropic support consisted in all cases
of dopamine and, if necessary, epinephrine and dobutamine.
Vasodilatatory treatment with sodium nitroprusside was given
in all cases. Diuretics (furosemide, single dosage 0.5 to 1 mg/
kg) were administered according to the clinical requirement.
All patients received volume substitution up to four hours post-
operatively and 16 patients up to 24 hours postoperatively,
which consisted mainly of blood transfusions, fresh frozen
plasma, or human albumin 5%. There was no significant
difference in postoperative volume substitution between the
two patient groups. Thrombotic events were defined as throm-
bus formation in veins, arteries, or cavities of the heart. They
were assessed/excluded by clinical examination, vessel
sonography, and echocardiography.
Data are shown in Table 2.
Table 1
Clinical diagnosis and underlying surgical procedures
Parameter TCPC group
n
BV repair group
n
Underlying diagnosis
Tricuspid atresia 5
Pulmonary atresia with or without VSD 3 6
Complex cardiac malformation 2 2
Palliative operations
Blalock-Taussig shunt 6 5
Glenn operation 3
Other procedures 2 7
Gender
Female 5 6
Male 5 2
Mean ± SEM Mean ± SEM
Cardiopulmonary bypass
Bypass time (minutes) 95 ± 13 217 ± 23
Cardiocirculatory arrest (minutes) 58 ± 2 45 ± 9a
Minimal oesophageal temperature (°C) 14.3 ± 0.5 16.6 ± 1.0
Aortic clamping time (minutes) 70 ± 6 131 ± 10
Mean ± SEM Mean ± SEM
Age at operation (months) 34 ± 5 100 ± 19
Weight at operation (kg) 12.4 ± 1.2 23.6 ± 4.1
Preoperative arterial oxygen saturation 
(percentage)
77 ± 2 86 ± 4
Total number of patients 10 8
aFour patients. BV, biventricular; SEM, standard error of the mean; TCPC, total cavopulmonary connection; VSD, ventricular septal defect.Critical Care    Vol 10 No 6    Heying et al.
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Methods
Laboratory tests
Blood samples were taken at 10 different time intervals before,
during, and after cardiac surgery as follows: preoperatively,
after heparin administration, 10 minutes after onset of CPB,
end of CPB, five minutes after protamine administration, four
hours postoperatively, 24 hours postoperatively, 48 hours
postoperatively, 72 hours postoperatively, and at discharge
between postoperative days 10 and 14. Venous blood was
collected before and after the operation. During CPB, blood
was withdrawn from the arterial line of the circuit. Each sample
consisted of 2 ml of blood anticoagulated with
ethylenediaminetetraacetic acid (EDTA). The samples were
immediately centrifuged for 10 minutes (3,000 rpm), and the
plasma was stored at -70°C until analysis.
Coagulation parameters
Routine laboratory parameters such as prothrombin time (PT),
partial thromboplastin time (PTT), antithrombin III (AT III), and
fibrinogen were assessed before surgery, four and 24 hours
postoperatively, and at discharge. Concentrations of proteins
C and S were evaluated preoperatively. Activated protein C
resistance was excluded in all patients.
Fragment 1+2
Cleavage of fragment 1+2 from prothrombin results in
thrombin formation. This fragment remains in the blood circu-
lation long enough to allow quantification of activation of the
blood coagulation process. Measurement of F1+2 was per-
formed by enzyme-linked immunosorbent assay (ELISA)
(Dade Behring Holding GmbH, Eschborn, Germany) based on
capture and labeled antibodies with peroxidase conversion of
phenyldiamine-dihydrochloride.  The colour formation after
conversion was measured at 492 nm. In healthy adults, con-
centrations range between 0.4 and 1.1 nmol/l.
TFPI
TFPI activity can be measured by the catalytic activity of the
VIIa/TF complex to activate factor X to Xa. The measurement
in EDTA plasma was performed by means of the extent of inhi-
bition of substrate cleavage by factor Xa, which was deter-
mined by a colorimetric assay (American Diagnostica Inc.,
Stamford, CT, USA). Normal range in human plasma has not
Table 2
Postoperative clinical data
Parameter TCPC group
Mean ± SEM
BV repair group
Mean ± SEM
Inotropic support (μg/kg per minute)
Dopamine 4.85 ± 0.09 4.74 ± 0.27
Epinephrine 0.09 ± 0.02 0.08 ± 0.03
Dobutamine 5.15a 7.39 ± 1.32b
Sodium nitroprusside 0.98 ± 0.07 0.81 ± 0.21
Duration of mechanical ventilation (days) 5.3 ± 1.2 2.0 ± 0.8
Duration of intensive care treatment (days) 12.9 ± 2.5 3.6 ± 0.8
Blood transfusions up to four hours 
postoperatively (ml/kg)
Mean ± SEM Mean ± SEM
Erythrocytes 8.9 ± 1.3 11.6 ± 5.1
Human albumin 5% 12.0 ± 4.0 11.0 ± 4.3
Fresh frozen plasma 11.9 ± 0.6 8.3 ± 1.1
CPB blood 16.2 ± 6.1 8.3 ± 1.4
Blood transfusions 4 to 24 hours 
postoperatively (ml/kg)
Mean ± SEM Mean ± SEM
Erythrocytes 90.0a 9.0 ± 1.7
Human albumin 5% 22.4 ± 3.7 7.2 ± 0.4
Fresh frozen plasma 11.7 ± 1.3
CPB blood 11.2a
aOne patient; bthree patients. BV, biventricular; CPB, cardiopulmonary bypass; SEM, standard error of the mean; TCPC, total cavopulmonary 
connection.Available online http://ccforum.com/content/10/6/R165
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been generally established yet. Single studies show adult val-
ues between 0.83 and 1.14 U/ml [7].
TxB2
TxB2 was measured by means of an enzyme immunoassay
(Biotrak; Amersham, now part of GE Healthcare, Little Chal-
font, Buckinghamshire, UK), based on competition of labeled
TxB2 with sample TxB2. In this test, the label was a peroxi-
dase, which converts the substrate tetramethylbenzidine,
yielding a yellow colour, which is measured at 450 nm. This
assay is very sensitive, being validated to 3.6 pg/ml. Such low
concentrations are expected to be found in plasma obtained
from healthy volunteers [15].
MCP-1
MCP-1 was measured by means of a sandwich ELISA based
on a monoclonal capture antibody and a chromogen substrate
labeled second antibody (R&D Systems, Inc., Minneapolis,
MN, USA). Normal values in adults range from 70 to 300 pg/
ml.
Statistical analysis
Results are expressed as the mean value ± standard error of
the mean. Data were analysed with the SPSS for Windows
software, version 12 (SPSS GmbH Software, München, Ger-
many). Non-normally distributed variables were analysed by
non-parametric tests. Time-dependent variations of biologic
variables were analysed by the Wilcoxon test and intergroup
comparisons by the Mann-Whitney U test. Alpha adjustment
for repeated comparisons was performed according to Bon-
ferroni-Holm. The Fisher exact test was used for the analysis
of categorical data and the Spearman correlation coefficient
for correlation analysis. Probability values less than 0.05 were
considered significant.
Results
Clinical data
Patients' diagnosis, clinical data, and operation parameters
are summarised in Table 1. Children undergoing BV repair
were significantly older (p < 0.01) but showed similar preop-
erative oxygen saturation than children undergoing TCPC.
CPB time and aortic cross-clamping time, but not duration of
cardiocirculatory arrest, were significantly longer in children
undergoing BV repair (both p < 0.01). There was no difference
in minimal oesophageal temperature during CPB in both
groups.
Chylothorax occurred in two of the patients and non-chylous
pleural or pericardial effusions in 12 children. Nine patients
developed transient postoperative arrhythmias. One patient
showed multiple organ failure and received peritoneal dialysis.
There was no hospital mortality. Postoperative data are given
in Table 2.
Coagulation parameters and anticoagulant treatment at 
discharge
Levels for proteins C and S were normal in all patients preop-
eratively, and resistance against active protein C was not seen
in any of the patients (data not shown). Values for prothrombin
activity, PTT, fibrinogen, and AT III are given in Table 3. AT III
level was normal in only four patients: two in the TCPC group
and two in the BV group. In all other patients, AT III ranged
from 22% to 28% of normal. Seventeen of the 18 patients
were treated with heparin starting on day one postoperatively.
In contrast to patients after TCPC, patients after BV repair
received no anticoagulant treatment at discharge. Nine out of
10 children after TCPC were on anticoagulant treatment at
discharge: seven children received coumarin and two patients
acetylsalicylic acid. Thus, patients after TCPC showed signifi-
cantly lower prothrombin activity at discharge (p < 0.01). Val-
ues for fibrinogen were significantly lower after TCPC than
after BV 72 hours postoperatively (p < 0.01). Values for partial
PT were significantly higher after TCPC than after BV at dis-
charge (p < 0.03).
Coagulation activity
In all children, preoperative levels of F1+2, TxB2, or MCP-1
did not correlate with the age of the patients but TFPI did
(Spearman correlation coefficient = -0.68; p < 0.05). There
was no correlation between the preoperative arterial oxygen
saturation and the preoperative coagulation variables. Low AT
III concentrations correlated with higher F1+2, shorter PTT,
and more postoperative MCP-1. Values for F1+2 did not cor-
relate with TFPI or protein C values. After CPB, lower TFPI
concentration correlated with a shorter PT. Significant correla-
tions between coagulation parameters are shown in Table 4.
Prothrombin fragment 1+2
In all patients, preoperative plasma concentrations of F1+2
were increased in comparison with expected values in adults
(4.76 ± 1.39 nmol/l) and raised significantly after heparin
administration until 10 minutes after CPB (p < 0.01) to reach
a maximum value at the end of CPB (115.51 ± 23.75 mol/l).
Postoperatively, F1+2 concentrations decreased to reach
baseline values from the first postoperative day on.
There was no intergroup difference of F1+2 concentrations at
any time point in patients undergoing TCPC as compared with
those undergoing BV repair. Figure 2a shows the course of
F1+2 before, during, and after CPB for both patient groups.
An inverse correlation was found between the concentrations
of F1+2 at the end of CPB and five minutes after protamine
administration in relation to the minimal oesophageal tempera-
ture during CPB (Spearman correlation coefficients were -
0.69 [p < 0.01] and -0.51 [p < 0.05], respectively). There was
no correlation between duration of CPB, aortic clamping time,
or cardiocirculatory arrest time and F1+2 levels. Four patientsCritical Care    Vol 10 No 6    Heying et al.
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in the study had normal AT III concentrations. In those four
patients, almost no F1+2 was generated (Figure 3).
TFPI
Preoperative concentrations of TFPI were normal as com-
pared with values in adults (0.8 ± 0.1 U/l). After heparin admin-
istration and before connection to CPB, TFPI levels increased
significantly in comparison with preoperative values (5.97 ±
0.48 U/l; p < 0.01) as shown in Figure 2b. Ten minutes after
CPB, the TFPI levels were still significantly elevated in compar-
ison with preoperative values but decreased from the end of
CPB on to reach baseline values. TFPI levels were not differ-
ent between both patient groups before the operation but
were significantly lower in the TCPC group as compared with
the BV group 24 hours postoperatively (p < 0.01). There was
no correlation between duration of CPB, aortic clamping time,
or cardiocirculatory arrest time and TFPI levels.
TxB2
In all patients, preoperative TxB2 values (492.3 ± 110.3 pg/
ml) were higher than values observed in normal adults and
decreased at the beginning of CPB (321.68 ± 45.77 pg/ml)
as shown in Figure 2c. TxB2 values rose significantly 10 min-
utes after CPB to reach their peak at the end of CPB (1337.0
± 357.55 pg/ml; p < 0.01). Levels decreased significantly
again five minutes after protamine administration (p < 0.01)
and reached preoperative levels 72 hours postoperatively. The
concentrations of TxB2 were similar in both patient groups
before, during, and after CPB except 72 hours postopera-
tively. At that time point, the TCPC group showed significantly
higher concentrations than the BV group (p < 0.05). There
was no correlation between duration of CPB, aortic clamping
time, or cardiocirculatory arrest time and TxB2 levels.
MCP-1
In all patients, preoperative MCP-1 values were in the upper
Table 3
Course of coagulation parameters
Coagulation 
parameter
TCPC group Mean ± SEM BV repair group Mean ± SEM
Time point PT 
(percentage)
PTT 
(seconds)
Fibrinogen 
(mg/dl)
AT III 
(percentage)
PT 
(percentage)
PTT 
(seconds)
Fibrinogen 
(mg/dl)
AT III 
(percentage)
Preoperative 92.3 ± 2.5 32.2 ± 1.0 2.8 ± 0.2 43.8 ± 12.6 89.0 ± 8.0 36.0 ± 1.7 3.0 ± 0.2 46.9 ± 13.7
4 hours 
postoperative
62.3 ± 3.9 47.7 ± 5.6 1.5 ± 0.1 20.4 ± 4.1 70.9 ± 3.4 37.8 ± 1.7 1.7 ± 0.3 27.4 ± 6.9
24 hours 
postoperative
51.4 ± 6.2 39.5 ± 35.9 1.9 ± 0.2a 20.9 ± 4.7 62.8 ± 4.7 33.9 ± 2.4 2.9 ± 0.4a 38.5 ± 13.4
72 hours 
postoperative
75.5 ± 6.7 45.3 ± 11.9 2.8 ± 0.3a 37.9 ± 14.2 84.0 ± 8.5 33.5 ± 1.9 4.1 ± 0.5a 48.2 ± 17.7
At discharge 47.0 ± 8.5a 37.0 ± 1.7a nd nd 95.3 ± 1.8a 31.3 ± 1.6a nd nd
aSignificant difference (p ≤ 0.05) of values between the two groups. AT III, antithrombin III; BV, biventricular; nd, not diagnosed; PT, prothrombin 
time; PTT, partial thromboplastin time; SEM, standard error of the mean; TCPC, total cavopulmonary connection.
Table 4
Correlations of coagulation parameters
AT III (preoperative) AT III (four hours 
postoperative)
MCP-1 (four hours 
postoperative)
PT (four hours 
postoperative)
PTT (four hours 
postoperative)
F1+2 (end of CPB) Negative (p < 0.05) Negative (p < 0.01) Positive (p < 0.01)
F1+2 (five minutes 
after protamine)
Negative (p < 0.05) Negative (p < 0.01)
F1+2 (four hours 
postoperative)
Negative (p < 0.01) Positive (p < 0.01)
MCP-1 (four hours 
postoperative)
Negative (p < 0.05) Negative (p < 0.01)
TFPI (five minutes 
after protamin)
Positive (p < 0.05) Negative (p < 0.05)
AT III, antithrombin III; BV, biventricular; CPB, cardiopulmonary bypass; F1+2, prothrombin fragment 1+2; MCP-1, monocyte chemoattractant 
protein-1; PT, prothrombin time; PTT, partial thromboplastin time; TFPI, tissue factor pathway inhibitor.Available online http://ccforum.com/content/10/6/R165
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Figure 2
Perioperative course of prothrombin fragment 1 + 2 (F1+2), tissue factor pathway inhibitor (TFPI), thromboxane B2 (TxB2), and monocyte chemoat- tractant protein-1 (MCP-1) Perioperative course of prothrombin fragment 1 + 2 (F1+2), tissue factor pathway inhibitor (TFPI), thromboxane B2 (TxB2), and monocyte chemoat-
tractant protein-1 (MCP-1). (a) Time course of F1+2 in both patient groups. F1+2 concentrations increased after heparin, reaching a maximum value 
at the end of cardiopulmonary bypass (CPB). Postoperatively, F1+2 concentrations showed baseline values. (b) Time course of TFPI in both patient 
groups. TFPI levels increased after heparin administration and decreased from the end of CPB on to reach baseline values. **p < 0.01 comparing 
both patient groups. (c) Time course of TxB2 in both patient groups. TxB2 values decreased at the beginning of CPB and reached maximum values 
at the end of CPB. In the postoperative course, TxB2 levels were found to be similar to preoperative values. *p < 0.05 comparing both patient 
groups. (d) Time course of MCP-1 in both patient groups. MCP-1 concentrations increased during CPB to reach preoperative values five minutes 
after protamine administration. TCPC, total cavopulmonary connection.Critical Care    Vol 10 No 6    Heying et al.
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normal range for healthy children (288.66 ± 86.73 pg/ml).
MCP-1 concentrations decreased significantly 10 minutes
after CPB (86.79 ± 18.15 pg/ml; p < 0.01) compared with the
preoperative values as shown in Figure 2d. MCP-1 concentra-
tions increased during CPB to reach preoperative values five
minutes after protamine administration. This was followed by a
second significant decrease 48 hours after CPB (119.02 ±
14.68 pg/ml; p < 0.01). MCP-1 levels returned to baseline val-
ues at the time of discharge in all children. There was no sig-
nificant difference in MCP-1 levels before, during, and after
CPB between both patient groups. There was no correlation
between duration of CPB, aortic clamping time, or cardiocir-
culatory arrest time and MCP-1 levels.
Discussion
During CPB, accelerated thrombin generation plays a central
role in the development of haemostatic abnormalities [1-3,16].
Despite systemic application of heparin during CPB, thrombin
activation occurs mainly via the extrinsic coagulation pathway
[2,3]. However, the question of whether cardiac surgery with
CPB influences the perioperative balance between pro- and
anti-thrombotic activity in children with complex cardiac
defects has not been addressed so far.
In this study, we report an increased thrombin generation
despite liberation of TFPI as an effect of CPB in children
undergoing cardiac surgery for complex cyanotic cardiac
defect. We could confirm a procoagulant state related to car-
diac surgery under CPB, with significantly increased values of
F1+2, TxB2, and MCP-1 reaching a maximum at the end of
CPB. TFPI was liberated already before initiation of CPB, after
heparin administration. Its increase was short-lasting, with lev-
els returning to preoperative values at the end of bypass.
Increased thrombin generation determined by F1+2 levels
during cardiac surgery was also shown by others [17,18]. It is
generally accepted that thrombin is generated by the contact
between blood and the surface of the extracorporeal circuit by
initiation of factor X or XII as well as by tissue factor released
from the wound and activated monocytes [7,8,19]. We
observed an inverse correlation of F1+2 and AT III levels. Low
AT III concentrations of approximately 25% will allow more
thrombin activity and thus more generation of F1+2.
Procoagulant state
In our patients, the procoagulant state persisted in the early
postoperative period as shown by increased levels of F1+2 up
to the first postoperative day. These changes that are due to
CPB were not influenced by the type of cardiac surgery per-
formed in our patients [2,3]. The inverse correlation observed
between the minimal oesophageal temperature during CPB
and F1+2 suggests that hypothermia induces prothrombin
cleavage. This goes along with results of other investigations
reporting higher thrombin generation and higher platelet
aggregation due to deep hypothermia [20,21]. Thrombin and
plasmin generation were found to be independent of age in
children [4]. Our data confirm this. Therefore, we suggest that
age does not have a relevant impact on pro- and anti-throm-
botic balance.
In our series, slightly elevated values of F1+2 were still noticed
postoperatively and at discharge without any signs of clinical
thrombosis. This goes along with results of others showing
persistence of increased F1+2 values five days after the Fon-
tan operation [13].
Balance between pro- and anti-thrombotic activity
Anticoagulant activity of thrombin results in the release of TFPI
[2]. In our patients, levels of TFPI increased after heparin
Figure 3
Correlation between antithrombin III (AT III) values and prothrombin fragment 1+2 (F1+2) Correlation between antithrombin III (AT III) values and prothrombin fragment 1+2 (F1+2). Patients with normal AT III levels show almost no F1+2 
production in the peri- and postoperative courses. During cardiopulmonary bypass (CPB), low AT III correlates with high F1+2: **p < 0.01. post OP, 
postoperatively; pre OP, preoperatively.Available online http://ccforum.com/content/10/6/R165
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administration, reaching their peak value at that time point,
according to previous observations [7,8]. Although heparin
should reduce the generation and activity of thrombin,
thrombin generation as shown by elevated F1+2 was still
present in the course of the operation. This observation is
confirmed by others [17,18] and is even more present in chil-
dren compared with adults [22]. In addition, manifest thrombin
generation has been shown by measuring thrombin-anti-
thrombin complex, which was also found to be increased in
children after CPB compared with adults [22]. Preoperatively,
we observed low AT III and short PTT, particularly in the TCPC
group. This might explain, in part, the prothrombotic effects in
those patients during CPB.
The fact that we detected in vivo thrombin generation despite
increased levels of TFPI implies that the inhibition of tissue fac-
tor-dependent coagulation pathway was not efficient in pre-
venting thrombin generation during CPB [7]. The in vitro
laboratory PT correlated with TFPI, showing that TFPI as an
inhibitor protects against extrinsic clotting. However, TFPI is
quickly lost after its release due to heparin administration. Our
results suggest that TFPI activity at the end of CPB is insuffi-
cient to prevent thrombin generation.
It has been stated that the effect of heparin is inadequate in the
paediatric population if detected by ACT measurement [22].
As a consequence, a different monitoring and administration
of a higher dosage of heparin during CPB is suggested to
reduce thrombin formation [22].
Thrombin is also known as a potent platelet activator. In our
study, platelet activation was assessed by measuring TxB2.
TxB2 levels reached their peak levels at the end of bypass in
our patients. These results go along with other studies report-
ing that thromboxane values increase and remain elevated dur-
ing CPB [15,23-25]. The observed correlation between
cardiocirculatory arrest time and TxB2 five minutes after pro-
tamine administration suggests the importance of the opera-
tion technique. The major sources of TxB2 during CPB are
thought to be the ischaemic pulmonary tissue and the seques-
tered platelets [6,24]. The elevated TxB2 values displayed by
our patients 72 hours postoperatively could be caused by the
contact between blood and the abnormal intracardiac sur-
faces, increased shear stress, persistent platelet dysfunction
due to CPB, or chronic endothelial injury [6,23].
Interaction between coagulation and inflammation
MCP-1 plays an important role as a mediator between inflam-
mation that is elicited by CPB and coagulation [9,26-28].
MCP-1 upregulation is induced by thrombin-stimulated plate-
lets [29], while MCP-1 in turn induces accumulation of tissue
factor [30]. Platelet-monocyte aggregates contribute impor-
tantly to thrombosis in vital organs [31]. Increased levels of
MCP-1 correlated with a complicated postoperative course
after paediatric CPB [32].
Recent studies suggest that thrombin itself is a physiologic
mediator of inflammatory events [33-35]. Thrombin receptor
activation on leucocytes increases the release of inflammatory
cytokines [35]. Furthermore, thrombin contributes to the
inflammatory reaction by activating a family of protease-acti-
vated receptors, which stimulate cells to express cytokines
and chemokines [35]. In our study, this is reflected by a high
postoperative MCP-1. This increase seems to be generated
during CPB because it is correlated with higher F1+2 and
lower AT III. The postoperative increase of MCP-1 might con-
tribute to a higher risk of thromboembolic events in that period.
We did not observe any thromboembolic event in our patient
group, which might be due to the small number of patients
investigated. Long-term evaluations of MCP-1 levels in chil-
dren after cardiac surgery are mandatory to assess this. An
additional important observation of this study is the fact that
high levels of MCP-1 were already measured preoperatively
and also in the postoperative period until discharge of the
patients. Nevertheless, preoperative MCP-1 levels did not cor-
relate with postoperative levels.
Our group has previously described that children with congen-
ital cardiac defects show increased systemic and intramyocar-
dial release of proinflammatory cytokines [36]. Inflammatory
cytokines such as interleukin-1 or tumour necrosis factor-α
have a prothrombotic effect due to the activation of monocytes
and endothelial cells to express tissue factor [34,35]. Children
with congenital cardiac defects may therefore have increased
prothrombotic state, as suggested by our results showing
higher levels of MCP-1 than in healthy children.
Coagulation and complex congenital heart disease
Coagulation parameter abnormalities that could lead to a
higher risk for thromboembolic events such as decreases in
protein C, protein S, and plasminogen have been shown after
TCPC and, recently, also after partial cavopulmonary connec-
tion [37-39]. Recent studies have suggested that, in this latter
group of patients scheduled for TCPC, coagulation abnormal-
ities already exist before the operation, as shown by lower con-
centrations of protein C, factors II, V, VII, and X, plasminogen,
and AT III compared with age-matched controls [16].
AT III is known as a crucial parameter for outcome after cardiac
operation in adults [40]. However, in children, AT III levels
were shown to be lower than in adults, which is also
demonstrated in our results [41]. AT III consumption at this
stage is suggested. Interestingly, AT III values were already
low in our children before the operation. An influence of cya-
nosis or disturbed liver function might contribute to low AT III
levels in these children with complex cyanotic heart disease. In
our opinion, the preoperative state might be crucial to a con-
secutive imbalance in the coagulation system during bypass,
leading to thrombin generation. This is supported by the fact
that bypass time and the minimal oesophageal temperature
did not contribute to F1+2 production during bypass.Critical Care    Vol 10 No 6    Heying et al.
Page 10 of 11
(page number not for citation purposes)
As a consequence, in at-risk patients presenting with low AT
III levels, AT III replacement could be discussed as a beneficial
therapeutic option, but increased risk of bleeding in
connection with additional heparin therapy has to be taken in
account. It has been shown that AT III replacement in sepsis
patients does not lead to a clear benefit; especially in patients
co-treated with heparin, the outcome did not improve [42].
Our data show that patients with normal AT III values preoper-
atively show almost no thrombin generation during the peri-
and postoperative course, which might implicate a benefit of
AT III substitution in this patient group. At this stage, no data
are available in the literature which would justify a routinely
applied AT III replacement therapy in children undergoing
CPB. A controlled study would be needed to asses the influ-
ence of AT III replacement on coagulation disturbances in
CPB patients and their outcome.
Conclusion
Our data show profound coagulation abnormalities occurring
during CPB in children with complex congenital cardiac
defects undergoing cardiac surgery with an imbalance
between pro- and anti-thrombotic activity during CPB. This is
shown by the fact that high levels of procoagulant factors as
shown by F1+2 are not counterbalanced by anticoagulant fac-
tors such as TFPI and AT III. This imbalance is likely to enhance
the risk for thromboembolic events during and after cardiac
surgery, particularly in patients after univentricular palliation.
New studies should clarify whether a therapeutic strategy
aimed to enhance anti-thrombotic activity would be beneficial
for children undergoing cardiac operations.
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